15 results
8-K
EX-99.1
VERV
Verve Therapeutics Inc
10 Nov 21
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
6:56am
medicines. Backed by an expert team and a strong balance sheet, we stand well positioned to advance our gene editing therapies and fundamentally change
S-1
EX-10.17
VERV
Verve Therapeutics Inc
28 May 21
IPO registration
4:04pm
accountant or by an appraiser, financial advisor or other expert selected with the reasonable care by or on behalf of the Enterprise. The provisions
S-1
EX-10.13
VERV
Verve Therapeutics Inc
28 May 21
IPO registration
4:04pm
, reasonable attorneys’ fees, court costs, and expert fees as may be fixed by the court.
30. Appurtenant Rights. Subtenant shall have (as appurtenant
DRS
EX-10.14
VERV
Verve Therapeutics Inc
16 Apr 21
Draft registration statement
12:00am
, reasonable attorneys’ fees, court costs, and expert fees as may be fixed by the court.
30. Appurtenant Rights. Subtenant shall have (as appurtenant
S-1
EX-10.11
ousa cxq9
28 May 21
IPO registration
4:04pm
DRS
EX-10.12
e5u54eo6qr47cgdf a1w
16 Apr 21
Draft registration statement
12:00am
S-1
EX-10.9
u2uzn9s
28 May 21
IPO registration
4:04pm
DRS
EX-10.10
6dhi8vu2s1gn602z37
16 Apr 21
Draft registration statement
12:00am
DRS
EX-10.13
wef2m92k 6c6ek
16 Apr 21
Draft registration statement
12:00am
S-1
EX-10.12
pw8hcg
28 May 21
IPO registration
4:04pm
DRS
qepx68ufe
16 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next